BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Pfizer  Limited  submitted  on  7  December  2006  an  application  for  Marketing 
Authorisation to the European Medicines Agency (EMEA) for CELSENTRI, through the centralised 
procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The 
eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 27 July 2006. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The  application  submitted  is  a  complete  dossier  composed  of  administrative  information,  complete 
quality  data,  non-clinical  and  clinical  data  based  on  applicants’  own  tests  and  studies  and/or 
bibliographic literature substituting/supporting certain test(s) or study(ies). 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:   B. Ljungberg 
Co-Rapporteur: B. Silva Lima  
CHMP Peer reviewer:   E. Abadie 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 7 December 2006. 
The  request  for  Accelerated  Assessment  was  accepted  by  the  CHMP  on  14  December  2006 
subject to review at time of discussion of the List of Questions. 
The procedure started on 27 December 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  16  March 
2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 27 
March 2007. 
During  the  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 27 April 2007. 
The Accelerated Assessment was reviewed considering the consolidated List of Questions and 
during  the  meeting  on  23-26  April  2007  the  CHMP  decided  to  continue  to  assessment  under 
“normal” centralised timetable. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 22 May 
2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 5 June 2007. 
The  CHMP  agreed  on  a  list  of  outstanding  issues  to  be  addressed  by  the  applicant  in  an  oral 
explanation via written procedure on 14 June 2007. The final list of outstanding issues was sent 
to the applicant on 15 June 2007. 
During the CHMP meeting on 18-21 June 2007, the applicant gave an oral explanation in front 
of the CHMP. Furthermore, the CHMP agreed on a list of outstanding issues to be addressed in 
writing  by  the  applicant  including  a  list  of  questions  to  be  addressed  by  the  SAG  HIV/Viral 
Diseases. The final List of outstanding Issues as well as the list of questions to be addressed in 
front of the SAG was sent to the applicant on 21 June 2007. 
©EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
The applicant submitted the responses to the CHMP List of outstanding Issues on 27 June 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding Issues to all CHMP members on 9 July 2007. 
During a meeting of the SAG-HIV/Viral Diseases on 10 July 2007, experts were convened to 
address  questions  raised  by  the  CHMP.  The  applicant  gave  an  Oral  Explanation  during  this 
meeting. A report of this meeting was forwarded to the CHMP. 
During the meeting on 16-19 July 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to CELSENTRI on 19 July 2007. The applicant provided the letter of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 18 July 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 18 September 2007. 
©EMEA 2007 
2/2 
 
 
 
 
